Close

Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 17c; Issues Mixed Outlook

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 17c; Issues Mixed Outlook

Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results

August 9, 2016 4:05 PM EDT

DUBLIN, Aug. 9, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2016 and updated financial guidance for 2016.

"We have made significant progress in 2016, as we continue to build the foundation for future growth by further diversifying and strengthening our hematology/oncology portfolio with the addition of Vyxeos, a late-stage product candidate for the treatment of acute myeloid leukemia, through the acquisition of Celator Pharmaceuticals," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We achieved strong organic sales growth of our... More